Welcome to the international HTA database

Showing [23378 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2014	NIHR Health Technology Assessment programme	Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey
2005	Andalusian Health Technology Assessment Area (AETSA)	Use of flash sterilization
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of fentanyl and continuous electronic fetal monitoring in labour and delivery: a review of clinical effectiveness, safety, and clinical practice guidelines
2006	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Use of FDG-PET in clinical situations not addressed in the monitorized use of this technology. IPE-06/49
2017	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of extracorporeal membrane oxygenation for cardiac life support in adult subjects
2001	Agency for Healthcare Research and Quality (AHRQ)	Use of epoetin for anemia in chronic renal failure
2002	Blue Cross Blue Shield Association (BCBS)	Use of epithelial cell cytology in breast cancer risk assessment and high-risk patient management
2015	NIHR Health Technology Assessment programme	Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of diuretics for hypertension in patients with reduced renal function: a review of clinical effectiveness, safety, and guidelines
2014	Blue Cross Blue Shield Association (BCBS)	Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis
2010	Medical Advisory Secretariat (MAS)	Use of contrast agents with echocardiography in patients with suboptimal echocardiography
2009	NIHR Health Technology Assessment programme	Use of classical and novel biomarkers as prognostic risk factors for prostate cancer: a systematic review
2009	NIHR Health Technology Assessment programme	Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review
2008	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	Use of class 3b and class 4 lasers and intense pulsed light sources for cosmetic procedures in non-medical settings
2000	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Use of cisapride in patients with non-ulcer dyspepsia: a meta-analysis of randomized trials
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of chlorhexidine gluconate with alcohol for the prevention of peripheral intravenous device infections: a review of clinical and cost effectiveness, and guidelines
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of cetuximab (Erbitux®) within NHS Wales
1998	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Use of CDET gamma-cameras for conventional scintigraphy (systematic review, primary research, expert panel)
2004	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of carmustine implants (GLIADEL wafer) in patients with malignant glioma at The McGill University Health Centre
2015	Agency for Healthcare Research and Quality (AHRQ)	Use of cardiac resynchronization therapy in the Medicare population
2004	Alberta Heritage Foundation for Medical Research (AHFMR)	Use of cannabis or cannabinoids for non-malignant chronic pain
1995	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Use of calcitonin in idiopathic osteoporosis
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of bupropion in patients with depression and the associated risk of seizures: safety
2003	Institute for Clinical Effectiveness and Health Policy (IECS)	Use of botulinum toxine in the clinical practice
2001	Health Technology Advisory Committee (HTAC)	Use of botulinum toxin-A in pain associated with neuromuscular disorders
2007	Agency for Health Technology Assessment in Poland (AHTAPol)	Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis.
2005	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of Bortezomib (Velcade®) within NHS Wales
2016	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of biventricular pacing in atrioventricular heart block
2009	Agency for Healthcare Research and Quality (AHRQ)	Use of Bayesian techniques in randomized clinical trials: a CMS case study
2021	Ontario Health	Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of azathioprine in adults: safety
2005	Medical Advisory Secretariat (MAS)	Use of automated external defibrillators in cardiac arrest: an evidence-based analysis
2005	Medical Advisory Secretariat (MAS)	Use of automated external defibrillators in cardiac arrest - health technology literature review
2007	Agency for Healthcare Research and Quality (AHRQ)	Use of aspirin and NSAIDs to prevent colorectal cancer; an evidence synthesis
2011	Medical Services Advisory Committee (MSAC)	Use of artificial disc replacement in patients with cervical degenerative disc disease
2005	Health Council of the Netherlands Gezondheidsraad (GR)	Use of antiviral agents and other measures in an influenza pandemic
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of antipsychotics and/or benzodiazepines as rapid tranquilization in inpatients of mental facilities and emergency departments: a review of the clinical effectiveness and guidelines
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Use of anti-neuronal antibodies to diagnose paraneoplastic neurological syndromes
2013	HAYES, Inc.	Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)
2015	HAYES, Inc.	Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)
2010	HAYES, Inc.	Use of anti-infliximab antibody levels to monitor infliximab treatment
2007	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of alglucosidase alfa (Myozyme™) within NHS Wales
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of agalsidase beta (Fabrazyme®) within NHS Wales
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of adalimumab (Humira®) within NHS Wales
2007	Adelaide Health Technology Assessment (AHTA)	USCOM: Ultrasound cardiac output monitor for patients requiring haemodynamic monitoring
2006	Alberta Heritage Foundation for Medical Research (AHFMR)	USCOM for cardiac output monitoring
2005	Adelaide Health Technology Assessment (AHTA)	USCOM cardiac output monitor for ultrasonic cardiac output measurement in patients requiring haemodynamic monitoring
2006	Adelaide Health Technology Assessment (AHTA)	USCOM cardiac output monitor for patients requiring haemodynamic monitoring
2020	NIHR Health Technology Assessment programme	Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT
2020	Agency for Care Effectiveness (ACE)	Ursodeoxycholic acid for treating primary biliary cirrhosis
2016	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ursodeoxycholic acid (Ursofalk®)
2022	National Institute for Health and Care Excellence (NICE)	UroShield for preventing catheter-associated urinary tract infections. NICE medical technologies guidance 69
2011	HAYES, Inc.	UroLume urethral stent (American Medical Systems Inc.) for urinary obstruction secondary to benign prostatic hyperplasia (BPH)
2017	HAYES, Inc.	Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2016	HAYES, Inc.	UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2021	National Institute for Health and Care Excellence (NICE)	UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE medical technologies guidance 58
2020	NIHR Health Technology Assessment programme	Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine testing in long-term care: guidelines
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine testing in long-term care: clinical and cost effectiveness
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Urine pregnancy screening for patients with and without the capacity for pregnancy
2013	Penn Medicine Center for Evidence-based Practice (CEP)	Urine drug screening in chronic pain patients on opioid therapy
2010	Penn Medicine Center for Evidence-based Practice (CEP)	Urine drug screening in chronic pain patients on opioid therapy
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine based testing for gonorrhea and chlamydia: a review of diagnostic accuracy, cost-effectiveness, and compliance
2008	Medical Services Advisory Committee (MSAC)	Urinary metabolic profiling for detection of metabolic disorders
2008	Medical Services Advisory Committee (MSAC)	Urinary metabolic profile
2006	National Institute for Health and Care Excellence (NICE)	Urinary incontinence: the management of urinary incontinence in women
2001	Health Council of the Netherlands Gezondheidsraad (GR)	Urinary incontinence - review, expert panel
2010	HAYES, Inc.	Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment
2010	HAYES, Inc.	Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment
2014	Penn Medicine Center for Evidence-based Practice (CEP)	Urinalysis and urine culture specimens taken from old versus new urinary catheters in patients with suspected urinary tract infection
2019	National Institute for Health and Care Excellence (NICE)	UrgoStart for treating diabetic foot ulcers and leg ulcers. NICE medical technologies guidance 42
2007	HAYES, Inc.	Ureteral bulking agents for vesicoureteral reflux disease
1998	ECRI	Urea breath tests for detecting helicobacter pylori
2011	Institute for Clinical Evaluative Sciences (ICES)	Uptake of the new fee code for Ontario's enhanced 18-month well baby visit: a preliminary evaluation
1997	Scottish Health Purchasing Information Centre (SHPIC)	Uptake of breast cancer screening
2005	Institute for Clinical Evaluative Sciences (ICES)	Uptake and outcomes associated with cyclooxygenase (COX-2) inhibitors in Ontario's elderly
2014	HAYES, Inc.	Upright magnetic resonance imaging for diagnosis of spinal disorders
2008	HAYES, Inc.	Upright magnetic resonance imaging (MRI) for diagnosis of spinal disorders
2018	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Upper gastrointestinal endoscopy categorisation guidelines for adults
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Upper extremity deep vein thrombosis with peripherally inserted central catheters: a review of the guidelines
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea. 1st Update 2019
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Upper airway stimulation for moderate-to-severe sleep apnea
2007	Agency for Healthcare Research and Quality (AHRQ)	Updating systematic reviews
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Xpert MTB/RIF® test for tuberculosis
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: VERV™ patient managed transdermal neuromodulation system for overactive bladder syndrome
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: ThromboLUX™ for determining platelet quality
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: SpringTMS™ Total Migraine System
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: SoundBite™ hearing system
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: RhinoChill® intranasal cooling device for protective cooling the brain after a cerebral ischaemic event
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: RealTime mS9 Colorectal Cancer (CRC) Assay for the early detection of colorectal cancer
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Placental growth factor based tests for the diagnosis of pre-eclampsia
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: OVA1™ test for the assessment of suspected ovarian cancer
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Infrared lasers for treating onychomycosis
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: DuoFertility ovulation prediction system to aid natural conception
2013	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Caris Target Now™ molecular profiling service for solid malignant tumours
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Argus II™ retinal prosthesis system for peripheral retinal degeneration
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Amniotic fluid lactate™ monitoring system for dysfunctional labour
2012	NIHR Horizon Scanning Centre (NIHR HSC)	UPDATED: Alair® bronchial thermoplasty system for severe asthma
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Updated reports and recommendations on second- and third-line therapies for type 2 diabetes